🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
REGN
NASDAQ
🇺🇸 US
Regeneron Pharmaceuticals, Inc.
Pharmaceuticals
16Score
DipBuster Score™
$814.51
$13.21 (-1.6%)
Live price · Source: Yahoo
52-Week Position
$541.00
86% of range
$859.34
Beta
0.236
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.236
52W High$859.34
52W Low$541.00
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 86% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position86% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.236
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Regeneron Pharmaceuticals, Inc. (REGN), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-08-10 | Guarini Kathryn | SELL | 400 |
| 2026-08-10 | Guarini Kathryn | SELL | 400 |
| 2026-08-10 | Guarini Kathryn | BUY | 400 |
| 2026-08-10 | Zoghbi Huda Y | SELL | 800 |
| 2026-08-10 | Zoghbi Huda Y | SELL | 800 |
| 2026-08-10 | Zoghbi Huda Y | BUY | 800 |
| 2026-07-02 | Ryan Arthur F | SELL | 200 |
| 2026-05-01 | Ryan Arthur F | SELL | 2 |
| 2026-05-01 | Ryan Arthur F | SELL | 1 |
| 2026-05-01 | Ryan Arthur F | SELL | 5 |
Graham NCAV Analysis
Above net-net level
Current Assets$18.02B
Less: Total Liabilities−$9.30B
= Net Current Asset Value$8.72B
NCAV Per Share$62.5468
Current Price$843.47
Price / NCAV13.49×
Margin of Safety-1248.5%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.236
Dividend/yrNone
52W High$859.34
52W Low$541.00
52-Week Range
$541.00Now$859.34
86% through annual range
From 52W High−5.2%
From 52W Low+50.6%
📖 Plain English Summary
Regeneron Pharmaceuticals, Inc. is at 86% of its 52-week range. Beta 0.236 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for REGN
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — REGN
Heuristic · balance sheet, insider filings, price data, academic research
Regeneron Pharmaceuticals, Inc. — DipBuster Score 16/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Regeneron Pharmaceuticals, Inc. free
Add REGN to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
6/25
Momentum & Volume
5/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
4
/100 · NEUTRAL
dip depth
3/25
oversold rsi
0/25
mean reversion
2/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 16/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeu…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Leonard S. Schleifer
Staff
15,410 employees
Website